Recent optional goals set by the National Cholesterol Educational Program (NCEP) for low density lipoprotein cholesterol (LDL-C) are not being met by many millions of Americans.

Why bother to be interested in Lilly’s re-introduction of Humalog 50/50? I look forward to this as it comes closer to mimicking the bodies own insulin release, and for my patients it reduces the chance of nocturnal hypoglycemia. Learn more about how this formulation makes a difference by checking out …

The largest study ever to ask whether a low-fat diet reduces the risk of getting cancer or heart disease has found that the diet has no effect.

GSK Announces Approval And Availability Of Avandaryl(TM) (rosiglitazone Maleate And Glimepiride) Avandaryl is the first and only tablet to combine a thiazolidinedione (TZD), rosiglitazone maleate – separately marketed as Avandia(R) – with a sulfonylurea, glimepiride – separately marketed as Amaryl(R) – to help improve blood sugar control.

A Joslin Diabetes Center-led collaboration has documented for the first time subtle changes in the gray matter of the brain of type 1 diabetes patients.

Six new pharma treatment strategies in controlling diabetes.

Omron Healthcare announced on January 25 the results of its attitude survey on metabolic syndrome and visceral fat.

New Alpha-Glucosidase inhibitor for treatment of postprandial hyperglycemica released in India for the treatment of diabetes.

The high-fat “diet” that diabetic heart muscle consumes helps make cardiovascular disease the most common killer of diabetic patients. Diabetic heart muscle uses four times more fat for energy than the hearts of non-diabetics.

Diabetic neuropathic foot ulcers treated with REGRANEX® were 32 percent more likely to heal within 20 weeks than those not treated with REGRANEX®